Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemtuzumab Ozogamicin and Donor Leukocytes in Relapsed/Refractory AML
NCT03374332Phase 2Completed
- Sponsor
- Brown University
- Start
- Dec 2019
- Primary completion
- Sep 2023
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gemtuzumab ozogamicin in acute myeloid leukemia (AML), sponsored by Brown University. Started Dec 2019; status: completed.
02
Drugs
gemtuzumab ozogamicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03374332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03374332.